Candel Therapeutics, Inc. (NASDAQ:CADL – Get Rating) was the recipient of a significant growth in short interest in the month of December. As of December 15th, there was short interest totalling 51,000 shares, a growth of 38.6% from the November 30th total of 36,800 shares. Based on an average trading volume of 42,600 shares, the days-to-cover ratio is presently 1.2 days. Approximately 0.6% of the shares of the company are short sold.

Candel Therapeutics Stock Up 7.8 %

NASDAQ CADL traded up $0.13 during mid-day trading on Friday, reaching $1.79. 30,919 shares of the stock were exchanged, compared to its average volume of 53,339. The business's 50 day moving average is $1.76 and its 200-day moving average is $2.75. Candel Therapeutics has a 1 year low of $1.40 and a 1 year high of $8.10. The company has a debt-to-equity ratio of 0.40, a quick ratio of 13.41 and a current ratio of 13.41.

Candel Therapeutics (NASDAQ:CADL – Get Rating) last posted its quarterly earnings data on Thursday, November 10th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.53) by $0.23. The company had revenue of $0.03 million for the quarter. On average, equities analysts forecast that Candel Therapeutics will post -1.28 earnings per share for the current year.

Hedge Funds Weigh In On Candel Therapeutics

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on CADL shares. Credit Suisse Group lowered their price target on shares of Candel Therapeutics from $10.00 to $8.00 and set an "outperform" rating on the stock in a report on Wednesday, December 7th. HC Wainwright started coverage on shares of Candel Therapeutics in a report on Friday, December 2nd. They set a "buy" rating and a $11.00 price target on the stock.

Candel Therapeutics Company Profile

(Get Rating)

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.

See Also

• Get a free copy of the StockNews.com research report on Candel Therapeutics (CADL)
• MarketBeat: Week in Review 12/26 – 12/30
• The Dogs Of Tech: It's Time For A Bite Of These Stocks
• Does This Acquisition Make Microsoft a Bear Market Buy?
• Is Kintara Therapeutics A Hidden Gem?
• Should You Warm up to Generac Stock for the Winter?

Receive News & Ratings for Candel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Candel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.